The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-08. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
=== Photodynamic (PDT) mechanism === PDT can induce many cellular pathways, and its main purpose is to induce cell death, either by apoptosis or necrosis. The fundamental process of photodynamic reactions involves three elements: photosensitizers (PS), light of a specific wavelength, and oxygen present in the cell. The interaction of these three components produced a desirable effect inside targeted tissues. Apart from light and oxygen, photosensitizers are compounds designed to absorb light at particular wavelengths during therapy, which enables them to initiate therapeutic processes. Two pathway branches interact and contribute to different ratios during PDT therapy, affecting its efficiency. Both mechanisms have the same first stage. When cells absorb photosensitizers and are exposed to light that aligns with their absorption spectrum, these substances photo-excite from their stable ground state (S°) to an energised excited singlet state (S1). Some energy is emitted as fluorescence, remaining energy directs the photosensitizer molecule into triplet state T1. Type I pathway of photodynamic reaction: T1 state PS can then interact with nearby molecules. Energy transfers between the photosensitizer and other molecules in the form of hydrogen and electrons, resulting in the creation of free radicals and anion radicals. These radicals remain in ground state and react with oxygen, leading to the formation of reactive oxygen species (ROS) and superoxide anion radicals (O2•−), which further react with oxygen to generate ROS.
In the Southern Hemisphere, the Pole of Cold is currently located in Antarctica, at the Russian (formerly Soviet) Antarctic station Vostok at 78°28′S 106°48′E. On July 21, 1983, this station recorded a temperature of −89.2 °C (−128.6 °F). This is the lowest naturally occurring temperature ever recorded on Earth. Vostok station is located at the elevation of 3,488 m (11,444 ft) above sea level, far removed from the moderating influence of oceans (more than 1,000 km [620 mi] from the nearest sea coast), and high latitude that results in almost three months of civil polar night every year (early May to end of July), all combine to produce an environment where temperatures rarely rise above −25 °C (−13 °F) during summer and frequently fall below −70 °C (−94 °F) in winter. By comparison, the South Pole, due to its lower elevation, is, on average, 5 to 10 °C (9 to 18 °F) warmer than Vostok, and the lowest temperature ever recorded at the South Pole is −82.8 °C (−117 °F). It is generally thought that Vostok is not the coldest place in Antarctica, and there are locations (notably, Dome A) that are modestly colder on average. The now inactive Plateau Station, located on the central Antarctic plateau, recorded an average yearly temperature that was consistently lower than that of Vostok Station during the 37-month period that it was active in the late 1960s, with its average for the coldest month being several degrees lower than the same statistic for Vostok. Plateau Station never recorded a temperature that surpassed the record low set at Vostok.
== In degradation of drug delivery systems == Among various types of cancer, lung cancer, larynx cancer, mouth cancer, and breast cancer exhibit higher concentrations (10-40 mM) of GSH compared to healthy cells. Thus, drug delivery systems containing disulfide bonds, typically cross-linked micro-nanogels, stand out for their ability to degrade in the presence of high concentrations of glutathione (GSH). This degradation process releases the drug payload specifically into cancerous or tumorous tissue, leveraging the significant difference in redox potential between the oxidizing extracellular environment and the reducing intracellular cytosol. When internalized by endocytosis, nanogels encounter high concentrations of GSH inside the cancer cell. GSH, a potent reducing agent, donates electrons to disulfide bonds in the nanogels, initiating a thiol-disulfide exchange reaction. This reaction breaks the disulfide bonds, converting them into two thiol groups, and facilitates targeted drug release where it is needed most. This reaction is called a thiol-disulfide exchange reaction.
Sources: en.wikipedia.org
== Epigenetic effects == The honey bee queens and workers represent one of the most striking examples of environmentally controlled phenotypic polymorphism. Even if two larvae had identical DNA, one raised to be a worker, the other a queen, the two adults would be strongly differentiated across a wide range of characteristics including anatomical and physiological differences, longevity, and reproductive capacity. Queens constitute the female sexual caste and have large active ovaries, whereas female workers have only rudimentary, inactive ovaries and are functionally sterile. The queen–worker developmental divide is controlled epigenetically by differential feeding with royal jelly; this appears to be due specifically to the protein royalactin. A female larva destined to become a queen is fed large quantities of royal jelly; this triggers a cascade of molecular events resulting in development of a queen. It has been shown that this phenomenon is mediated by an epigenetic modification of DNA known as CpG methylation. Silencing the expression of an enzyme that methylates DNA in newly hatched larvae led to a royal jelly-like effect on the larval developmental trajectory; the majority of individuals with reduced DNA methylation levels emerged as queens with fully developed ovaries. This finding suggests that DNA methylation in honey bees allows the expression of epigenetic information to be differentially altered by nutritional input.
Additionally, diabetes can result from other specific causes, such as genetic conditions (monogenic diabetes syndromes like neonatal diabetes and maturity-onset diabetes of the young), diseases affecting the pancreas (such as pancreatitis), or the use of certain medications and chemicals (such as glucocorticoids or other specific drugs, including those used after organ transplantation). The number of people worldwide diagnosed as living with diabetes has increased sharply in recent decades, from 200 million in 1990 to 828 million in 2024. Diabetes accounts for some two million deaths each year, and more than half of those affected are unaware of their condition. It affects one in seven of the adult human population, with type 2 diabetes accounting for more than 95% of cases. These numbers have already risen beyond earlier projections of 783 million adults by 2045. The prevalence of the disease continues to increase, most dramatically in low-middle income nations, where it is now the seventh leading cause of death. Rates are similar in women and men. The global expenditure on diabetes-related healthcare is an estimated US$760 billion a year.
=== REM sleep behavior disorder === Melatonin is a safer alternative than clonazepam in the treatment of REM sleep behavior disorder – a condition associated with the synucleinopathies like Parkinson's disease and dementia with Lewy bodies. However, clonazepam may be more effective. In any case, the quality of evidence for both treatments is very low and it is unclear whether either is definitely effective.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.